Evidence map›Paper›PMID 40925523›Full record

ArticleThe journal of allergy and clinical immunology. In practice2025

Addition of dupilumab for patients with aspirin-exacerbated respiratory disease who have poor response to aspirin therapy after desensitization.

Pooja M Achanta, Joel Swirnoff, Rachel E Parigian, Tanya M Laidlaw, Kathleen M Buchheit

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pooja M AchantaDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, Mass.
Joel SwirnoffDivision of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass.
Rachel E ParigianDivision of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass.
Tanya M LaidlawDivision of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass; Department of Medicine, Harvard Medical School, Boston, Mass.
Kathleen M BuchheitDivision of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass; Department of Medicine, Harvard Medical School, Boston, Mass. Electronic address: kbuchheit@bwh.harvard.edu.

Funding

Therapeutic Control of Aspirin-Exacerbated Respiratory DiseaseU19AI095219 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Joshua A Boyce · 2011 to 2026
$29.1M
The Role of IL-5 and Local Nasal Polyp Immunoglobulin Production in Aspirin-Exacerbated Respiratory DiseaseK23AI139352 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BUCHHEIT, KATHLEEN MARY · 2019 to 2023
$1.0M
Patient-Oriented Research Mentorship and Training in Upper Airway Allergic and Inflammatory DiseasesK24AI180296 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Tanya Maria Laidlaw · 2024 to 2026
$522k
Biomarkers predicting nasal polyp recurrence in aspirin-exacerbated respiratory diseaseR21AI182809 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Kathleen Mary Buchheit · 2025 to 2026
$484k
NIAID NIH HHS K23 AI139352NIAID NIH HHS K24 AI180296NIAID NIH HHS R21 AI182809NIAID NIH HHS U19 AI095219
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40925523
PMCPMC12442906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.